Treatment and Outcomes of Atrial Fibrillation and Acute Coronary Syndrome in Sweden

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

14226 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-11-16

Study Completion Date

2018-03-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Many people who suffer from irregular heartbeats (atrial fibrillation) which might cause stroke, need to take blood thinners to prevent it. However, people with atrial fibrillation are also at increased risk of acute myocardial infarction or unstable angina pectoris (another heart condition marked by a chest pain, comprising so-called acute coronary syndrome for which another type of treatment that prevents blood from clotting (antiplatelet treatment) is indicated. In particularly if such patients undergo percutaneous coronary intervention, a procedure aimed to open up diseased blood vessels and hence to treat acute coronary syndrome, this treatment is needed. If a patients takes several anti-clotting blood drugs, the risk of bleeding is high. The number of possible drug combinations and treatment durations is large. This study will help us to understand which anti-clotting drug combinations are prescribed in real life among patients with atrial fibrillation and acute coronary syndrome, how effective and safe they are for patients. The study will look into the data that are already available in several very large Swedish databases which contain information needed for the research.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Atrial Fibrillation: Risk and Benefits of Anti-coagulation in the Elderly

NCT03828162

Anticoagulants Causing Adverse Effects in Therapeutic Use Atrial Fibrillation Frail Elderly Syndrome

COMPLETED

DeteCtiON and Stroke PreventIon by MoDEl ScRreenING for Atrial Fibrillation

NCT05838781

Atrial Fibrillation Atrial Flutter

COMPLETED NA

Management of Antithrombotic TherApy in Patients With Atrial Fibrillation or DevelOping AtRial Fibrillation During Hospitalization for PCI

NCT03656523

Acute Coronary Syndrome Atrial Fibrillation

COMPLETED

Atrial Fibrillation Incidence, Risk Factors and Genetics

NCT00021905

Atrial Fibrillation Cardiovascular Diseases Heart Diseases +3 more

COMPLETED

Use of Oral Anticoagulants and Symptoms in Patients With Atrial Fibrillation in Örebro County

NCT04233515

Atrial Fibrillation Stroke, Ischemic

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

AF and ACS patients: No PCI

Patients with Atrial Fibrillation and Acute Coronary Syndrom who did not undergo a Percutaneous Coronary Intervention

Antithrombotic agents

Intervention Type DRUG

Antiplatelets and anticoagulants purchased 4 months before and within 7 days after the index date

AF and ACS patients: PCI without stent

Patients with Atrial Fibrillation and Acute Coronary Syndrom who underwent PCI without stent implantation (NOMESCO code FNG00-96 except FNG05)

Antithrombotic agents

Intervention Type DRUG

Antiplatelets and anticoagulants purchased 4 months before and within 7 days after the index date

AF and ACS patients: PCI with stent

Patients with Atrial Fibrillation and Acute Coronary Syndrom who underwent PCI with stent implantation (NOMESCO code FNG05)

Antithrombotic agents

Intervention Type DRUG

Antiplatelets and anticoagulants purchased 4 months before and within 7 days after the index date

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Antithrombotic agents

Antiplatelets and anticoagulants purchased 4 months before and within 7 days after the index date

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of ACS defined by a hospital discharge (ICD-10 code of I21 for myocardial infarction or I20.0 for unstable angina pectoris (with or without sub-codes) during the study period and a diagnosis of AF (ICD-10 code I48 with or without sub-codes) in the Patient Register before or on the same day as the patient was discharged for ACS.